Guggenheim Securities Initiates Coverage On NeuBase Therapeutics with Buy Rating, Announces $13 Price Target

Guggenheim Securities analyst Whitney Ijem initiates coverage on NeuBase Therapeutics (NASDAQ:NBSE) with a Buy rating and a $13 price target.

Benzinga · 02/07/2020 11:06

Guggenheim Securities analyst Whitney Ijem initiates coverage on NeuBase Therapeutics (NASDAQ:NBSE) with a Buy rating and a $13 price target.